Core regions in immunoglobulin heavy chain enhancers essential for survival of non-Hodgkin lymphoma cells are identified by a CRISPR interference screen
Marta Elżbieta Kasprzyk,
Weronika Sura,
Marta Podralska,
Marta Kazimierska,
Annika Seitz,
Wojciech Łosiewski,
Tomasz Woźniak,
Jeroen E. J. Guikema,
Arjan Diepstra,
Joost Kluiver,
Anke van den Berg,
Natalia Rozwadowska,
Agnieszka Dzikiewicz-Krawczyk
Affiliations
Marta Elżbieta Kasprzyk
Institute of Human Genetics, Polish Academy of Sciences, Poznań
Weronika Sura
Institute of Human Genetics, Polish Academy of Sciences, Poznań
Marta Podralska
Institute of Human Genetics, Polish Academy of Sciences, Poznań
Marta Kazimierska
Institute of Human Genetics, Polish Academy of Sciences, Poznań
Annika Seitz
Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen
Wojciech Łosiewski
Institute of Human Genetics, Polish Academy of Sciences, Poznań
Tomasz Woźniak
Institute of Human Genetics, Polish Academy of Sciences, Poznań
Jeroen E. J. Guikema
Department of Pathology, Amsterdam University Medical Center, Amsterdam
Arjan Diepstra
Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen
Joost Kluiver
Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen
Anke van den Berg
Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen
Natalia Rozwadowska
Institute of Human Genetics, Polish Academy of Sciences, Poznań
Agnieszka Dzikiewicz-Krawczyk
Institute of Human Genetics, Polish Academy of Sciences, Poznań
Chromosomal translocations in non-Hodgkin lymphoma (NHL) result in activation of oncogenes by placing them under the regulation of immunoglobulin heavy chain (IGH) super-enhancers. Aberrant expression of translocated oncogenes induced by enhancer activity can contribute to lymphomagenesis. The role of the IGH enhancers in normal B-cell development is well established, but knowledge regarding the precise mechanisms of their involvement in control of the translocated oncogenes is limited. The goal of this project was to define the critical regions in the IGH regulatory elements and identify enhancer RNAs (eRNA). We designed a sgRNA library densely covering the IGH enhancers and performed tiling CRISPR interference screens in three NHL cell lines. This revealed three regions crucial for NHL cell growth. With chromatin-enriched RNA-Seq we showed transcription from the core enhancer regions and subsequently validated expression of the eRNAs in a panel of NHL cell lines and tissue samples. Inhibition of the essential IGH enhancer regions decreased expression of eRNAs and translocated oncogenes in several NHL cell lines. The observed expression and growth patterns were consistent with the breakpoints in the IGH locus. Moreover, targeting the Eμ enhancer resulted in loss of B-cell receptor expression. In a Burkitt lymphoma cell line, MYC overexpression partially rescued the phenotype induced by IGH enhancer inhibition. Our results indicated the most critical regions in the IGH enhancers and provided new insights into the current understanding of the role of IGH enhancers in B-cell NHL. As such, this study forms a basis for development of potential therapeutic approaches.